Literature DB >> 21338443

A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity.

C Depondt1, P Godard, R S Espel, A L Da Cruz, P Lienard, M Pandolfo.   

Abstract

BACKGROUND AND
PURPOSE: It is widely acknowledged that individual response to antiepileptic drugs (AEDs) is influenced by genetic factors. However, most of the underlying genes and genetic variants remain unidentified to date. The purpose of this study is to examine the role of common variants in a number of candidate genes in the response to commonly prescribed AEDs.
METHODS: We recruited 495 patients with epilepsy. Patients were classified according to their response to several AEDs. We genotyped 104 polymorphisms in 17 candidate genes for AED response. We looked for statistically significant associations between these polymorphisms and well-defined AED response phenotypes.
RESULTS: We identified significant associations of CYP2C9 variant alleles with presence of phenytoin (PHT) adverse drug reactions (ADRs) and of GSTM1 copy number variation with the presence of carbamazepine ADRs. The latter association could not be confirmed in a replication study.
CONCLUSIONS: Our study is the first comprehensive candidate gene association study in epilepsy pharmacogenetics. Our results confirm the role of CYP2C9 variants in PHT toxicity. No other definite associations were identified. Large-scale efforts are needed to unravel the genetic determinants of AED response.
© 2011 The Author(s). European Journal of Neurology © 2011 EFNS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21338443     DOI: 10.1111/j.1468-1331.2011.03361.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  15 in total

1.  Current Principles in the Management of Drug-Resistant Epilepsy.

Authors:  Nathan A Shlobin; Josemir W Sander
Journal:  CNS Drugs       Date:  2022-05-20       Impact factor: 6.497

Review 2.  Cytochrome P450-mediated estrogen catabolism therapeutic avenues in epilepsy.

Authors:  Megha Gautam; Ganesh Thapa
Journal:  Acta Neurol Belg       Date:  2020-08-02       Impact factor: 2.396

Review 3.  Genetics as a molecular window into recovery, its treatment, and stress responses after stroke.

Authors:  Vanessa Juth; E Alison Holman; Michelle K Chan; Steven C Cramer
Journal:  J Investig Med       Date:  2016-04-04       Impact factor: 2.895

Review 4.  Pharmacogenomic considerations for medications in the perioperative setting.

Authors:  Ellie H Jhun; Jeffrey L Apfelbaum; David M Dickerson; Sajid Shahul; Randall Knoebel; Keith Danahey; Mark J Ratain; Peter H O'Donnell
Journal:  Pharmacogenomics       Date:  2019-07       Impact factor: 2.638

Review 5.  Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms.

Authors:  Ro-Lan Dao; Shih-Chi Su; Wen-Hung Chung
Journal:  Asia Pac Allergy       Date:  2015-04-29

Review 6.  Pharmacogenomics in epilepsy.

Authors:  Simona Balestrini; Sanjay M Sisodiya
Journal:  Neurosci Lett       Date:  2017-01-10       Impact factor: 3.046

Review 7.  Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region.

Authors:  Renée Dagenais; Kyle John Wilby; Hazem Elewa; Mary H H Ensom
Journal:  Drugs R D       Date:  2017-09

8.  Presence of a single nucleotide polymorphism (RS3758581) in a boy with DRESS syndrome.

Authors:  Hulya Anil; Koray Harmanci; Rahmi T Tekin; Abdulkadir Kocak
Journal:  Cent Eur J Immunol       Date:  2017-12-30       Impact factor: 2.085

Review 9.  CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment.

Authors:  Carlos Eduardo Silvado; Vera Cristina Terra; Carlos Alexandre Twardowschy
Journal:  Pharmgenomics Pers Med       Date:  2018-03-29

10.  Study of the allelic variants CYP2C9*2 and CYP2C9*3 in samples of the Peruvian mestizo population

Authors:  Ángel Tito Alvarado; Ana María Muñoz; Berta Loja; Jessica Michiko Miyasato; Jorge Antonio García; Roberto Andrés Cerro; Luis Abel Quiñones; Nelson Miguel Varela
Journal:  Biomedica       Date:  2019-09-01       Impact factor: 0.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.